<DOC>
	<DOCNO>NCT01666951</DOCNO>
	<brief_summary>The purpose study evaluate pharmacokinetics LCP-Tacro tablet administer once-daily compare Prograf capsule administer twice-daily kidney transplantation .</brief_summary>
	<brief_title>Multicenter , Prospective , Rand , PK Study LCP-Tacro™ Compared Prograf® Capsules De Novo Adult Kidney Transplant</brief_title>
	<detailed_description>This 2-arm , parallel group , prospective , double-blind , double-dummy , multicenter , clinical trial evaluate pharmacokinetics LCP-Tacro tablet daily comparison Prograf capsule twice-daily kidney transplantation .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Inclusion criterion Give write consent Male female subject age 18 70 year , inclusive Must receive primary secondary renal allograft decease donor non HLA identical living donor WOCBP must negative pregnancy test Must negative crossmatch test ABOcompatible Must able swallow tablet capsule Exclusion criterion Recipients previous nonrenal concurrent transplant Have panel reactive antibody &gt; 50 % Any condition may affect study drug absorption BMI &lt; 18 kg/m2 &gt; 45 kg/m2 History alcohol abuse le 6 month sobriety History recreational drug abuse le 6 month document abstinence Screening 12lead ECG demonstrate CS abnormality ( include QTc prolongation ) WOCBP either pregnant , lactating , plan become pregnant positive serum urine pregnancy test Subjects ( male female ) reproductive potential unwilling/unable use doublebarrier method Oral temperature ( prior study drug dose ) 38.0ºC high CS active infection ( eg , require hospitalization , judge Investigator ) Known hereditary immunodeficiency Malignancies history malignancy ( within last 5 year ) exception local , noninvasive , fully excise cutaneous basal cell carcinoma , cutaneous squamous cell carcinoma , cervical carcinoma situ Expect receive within 2 month randomization , receive within 3 month prior screen , follow : sirolimus , everolimus , belatacept , cyclophosphamide Any psychiatric medical condition , Investigator 's opinion , may put subject significant risk , may confound study result , may interfere significantly subject 's participation study Clinically symptomatic CHF document EJF le 45 % Significant COPD , pulmonary restrictive disease significant pulmonary hypertension Enrolled another investigational drug device study , less 30 day since discontinue Laboratory variable abnormal ( outside laboratory reference range ) CS Positive result follow serological test : human immunodeficiency virus ( HIV ) 1 antibody , hepatitis B virus ( HBV ) surface antigen ( HBsAg ) , antihepatitis B core antibody ( HBcAb ) , antihepatitis C virus ( HCV ) antibody ( HCV Ab ) Subjects primary focal segmental glomerulosclerosis Donor parameter must include follow known condition : Donor positive serological test result HIV1 , HBV HCV Donor history malignant disease ( current historical ) Cold ischemia time &gt; 30 hour Nonheartbeating donor</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>